Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2009

French Government Awards TcL Roughly $3.15M for Research on CD28 Antagonists in Transplant Therapy

  • French biopharma company TcL Pharma received a €2.2 million (about $3.15 million) grant from the French National Research Agency to help fund its Tolestim project, which focuses on long-acting CD28 antagonists for the improved tolerance in transplantation.

    The research project will involve a collaboration between TcL and and Inserm laboratory, which has developed a new approach to immunosuppression based on selective CD28 antagonists. TcL’s role will include preclinical validation of the immunomodulatory effects of CD28, preparation for Phase I and IIa trials in healthy volunteers and kidney transplant patients, plus development of an industrial-scale biomanufacturing process.

    The ANR grant comes just weeks after TcL completed a €1 million (roughly $1.43 million) equity financing round as part of France’s TEPA economic stimulus package. 

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »